Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 240

1.

Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.

Schuler E, Frank F, Hildebrandt B, Betz B, Strupp C, Rudelius M, Aul C, Schroeder T, Gattermann N, Haas R, Germing U.

Leuk Res. 2018 Feb;65:1-4. doi: 10.1016/j.leukres.2017.12.002. Epub 2017 Dec 5.

PMID:
29216536
2.

New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types.

Strupp C, Nachtkamp K, Hildebrandt B, Giagounidis A, Haas R, Gattermann N, Bennett JM, Aul C, Germing U.

Leuk Res. 2017 Jun;57:78-84. doi: 10.1016/j.leukres.2017.02.008. Epub 2017 Feb 27.

PMID:
28324772
3.

Dysplastic erythroid precursors in the myelodysplastic syndromes and the acute myeloid leukemias: Is there biologic significance? (How should blasts be counted?).

Bennett JM, Tuechler H, Aul C, Strupp C, Germing U.

Leuk Res. 2016 Aug;47:63-9. doi: 10.1016/j.leukres.2016.05.006. Epub 2016 May 12.

PMID:
27258735
4.

Causes of death in 2877 patients with myelodysplastic syndromes.

Nachtkamp K, Stark R, Strupp C, Kündgen A, Giagounidis A, Aul C, Hildebrandt B, Haas R, Gattermann N, Germing U.

Ann Hematol. 2016 May;95(6):937-44. doi: 10.1007/s00277-016-2649-3. Epub 2016 Mar 30.

PMID:
27025507
5.

[Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias].

Kossak-Roth U, Saußele S, Aul C, Büchner T, Döhner H, Dugas M, Ehninger G, Ganser A, Giagounidis A, Gökbuget N, Griesshammer M, Hasford J, Heuser M, Hiddemann W, Hochhaus A, Hoelzer D, Niederwieser D, Reiter A, Röllig C, Hehlmann R.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Apr;59(4):444-53. doi: 10.1007/s00103-016-2315-x. Review. German.

PMID:
26979719
6.

Impaired formation of erythroblastic islands is associated with erythroid failure and poor prognosis in a significant proportion of patients with myelodysplastic syndromes.

Buesche G, Teoman H, Giagounidis A, Göhring G, Schlegelberger B, Ganser A, Aul C, Kreipe HH.

Haematologica. 2016 May;101(5):e177-81. doi: 10.3324/haematol.2015.129015. Epub 2016 Mar 4. No abstract available.

7.

Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia.

Krug U, Berdel WE, Gale RP, Haferlach C, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Staib P, Beelen D, Serve H, Schliemann C, Stelljes M, Balleisen L, Maschmeyer G, Grüneisen A, Eimermacher H, Giagounidis A, Rasche H, Hehlmann R, Lengfelder E, Thiel E, Reichle A, Aul C, Ludwig WD, Kern W, Haferlach T, Köpcke W, Görlich D, Sauerland MC, Heinecke A, Wörmann BJ, Hiddemann W, Büchner T.

Leukemia. 2016 Jun;30(6):1230-6. doi: 10.1038/leu.2016.25. Epub 2016 Feb 9.

PMID:
26859081
8.

Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group.

Lübbert M, Suciu S, Hagemeijer A, Rüter B, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Schaefer HE, Bogatyreva L, Aul C, de Witte T, Ganser A, Becker H, Huls G, van der Helm L, Vellenga E, Baron F, Marie JP, Wijermans PW; EORTC Leukemia Group and the German MDS Study Group.

Ann Hematol. 2016 Jan;95(2):191-9. doi: 10.1007/s00277-015-2547-0. Epub 2015 Nov 23.

PMID:
26596971
9.

Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia.

Alpermann T, Schnittger S, Eder C, Dicker F, Meggendorfer M, Kern W, Schmid C, Aul C, Staib P, Wendtner CM, Schmitz N, Haferlach C, Haferlach T.

Haematologica. 2016 Feb;101(2):e55-8. doi: 10.3324/haematol.2015.133819. Epub 2015 Oct 15. No abstract available.

10.

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.

Gratwohl A, Pfirrmann M, Zander A, Kröger N, Beelen D, Novotny J, Nerl C, Scheid C, Spiekermann K, Mayer J, Sayer HG, Falge C, Bunjes D, Döhner H, Ganser A, Schmidt-Wolf I, Schwerdtfeger R, Baurmann H, Kuse R, Schmitz N, Wehmeier A, Fischer JT, Ho AD, Wilhelm M, Goebeler ME, Lindemann HW, Bormann M, Hertenstein B, Schlimok G, Baerlocher GM, Aul C, Pfreundschuh M, Fabian M, Staib P, Edinger M, Schatz M, Fauser A, Arnold R, Kindler T, Wulf G, Rosselet A, Hellmann A, Schäfer E, Prümmer O, Schenk M, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Büsche G, Haferlach C, Schnittger S, Müller MC, Reiter A, Berger U, Saußele S, Hochhaus A, Hehlmann R; SAKK; German CML Study Group.

Leukemia. 2016 Mar;30(3):562-9. doi: 10.1038/leu.2015.281. Epub 2015 Oct 14.

11.

Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG).

Becker H, Suciu S, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Hagemeijer A, Schaefer HE, Fiaccadori V, Baron F, Ganser A, Aul C, de Witte T, Wijermans PW, Lübbert M.

Ann Hematol. 2015 Dec;94(12):2003-13. doi: 10.1007/s00277-015-2489-6. Epub 2015 Sep 24.

PMID:
26400023
12.

Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group.

Braulke F, Müller-Thomas C, Götze K, Platzbecker U, Germing U, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Hildebrandt B, Aul C, Stauder R, Valent P, Fonatsch C, Bacher U, Trümper L, Haase D, Schanz J.

Genes Chromosomes Cancer. 2015 Dec;54(12):809-17. doi: 10.1002/gcc.22292. Epub 2015 Sep 10.

PMID:
26355708
13.

Change of prognosis of patients with myelodysplastic syndromes during the last 30 years.

Neukirchen J, Nachtkamp K, Schemenau J, Aul C, Giagounidis A, Strupp C, Kuendgen A, Kobbe G, Haas R, Germing U.

Leuk Res. 2015 Jul;39(7):679-83. doi: 10.1016/j.leukres.2015.04.001. Epub 2015 Apr 15.

PMID:
25929166
14.

Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes.

Schemenau J, Baldus S, Anlauf M, Reinecke P, Braunstein S, Blum S, Nachtkamp K, Neukirchen J, Strup C, Aul C, Haas R, Gattermann N, Germing U.

Eur J Haematol. 2015 Sep;95(3):181-9. doi: 10.1111/ejh.12512. Epub 2015 May 15. Review.

PMID:
25600827
15.

Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.

Braulke F, Platzbecker U, Müller-Thomas C, Götze K, Germing U, Brümmendorf TH, Nolte F, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, Solé F, Mallo M, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Shirneshan K, Aul C, Stauder R, Sperr WR, Valent P, Fonatsch C, Trümper L, Haase D, Schanz J.

Haematologica. 2015 Feb;100(2):205-13. doi: 10.3324/haematol.2014.110452. Epub 2014 Oct 24.

16.

Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies.

Oosterveld M, Suciu S, Muus P, Germing U, Delforge M, Belhabri A, Aul C, Selleslag D, Ferrant A, Marie JP, Amadori S, Jehn U, Mandelli F, Hess U, Hellström-Lindberg E, Cakmak-Wollgast S, Vignetti M, Labar B, Willemze R, de Witte T.

Ann Hematol. 2015 Jan;94(1):23-34. doi: 10.1007/s00277-014-2177-y. Epub 2014 Aug 7.

PMID:
25096636
17.

Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study.

Neukirchen J, Lauseker M, Blum S, Giagounidis A, Lübbert M, Martino S, Siragusa S, Schlenk RF, Platzbecker U, Hofmann WK, Götze K, Palumbo GA, Magrin S, Kündgen A, Aul C, Hildebrandt B, Hasford J, Kobbe G, Haas R, Germing U.

Leuk Res. 2014 Jan;38(1):57-64. doi: 10.1016/j.leukres.2013.10.013. Epub 2013 Oct 26.

PMID:
24238640
18.

Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.

Fernandez-Mercado M, Burns A, Pellagatti A, Giagounidis A, Germing U, Agirre X, Prosper F, Aul C, Killick S, Wainscoat JS, Schuh A, Boultwood J.

Haematologica. 2013 Dec;98(12):1856-64. doi: 10.3324/haematol.2013.086686. Epub 2013 Jul 5.

19.

Monosomal karyotype in MDS: explaining the poor prognosis?

Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Grau J, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D.

Leukemia. 2013 Oct;27(10):1988-95. doi: 10.1038/leu.2013.187. Epub 2013 Jun 21.

PMID:
23787396
20.

Recombination of allyl radicals in the high temperature fall-off regime.

Lynch PT, Annesley CJ, Aul CJ, Yang X, Tranter RS.

J Phys Chem A. 2013 Jun 13;117(23):4750-61. doi: 10.1021/jp402484v. Epub 2013 Jun 4.

PMID:
23679185
21.

Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts.

Maassen A, Strupp C, Giagounidis A, Kuendgen A, Nachtkamp K, Hildebrandt B, Gattermann N, Aul C, Haas R, Germing U.

Leuk Res. 2013 Jan;37(1):64-70. doi: 10.1016/j.leukres.2012.09.021. Epub 2012 Oct 31.

PMID:
23122806
22.

Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.

Lengfelder E, Hanfstein B, Haferlach C, Braess J, Krug U, Spiekermann K, Haferlach T, Kreuzer KA, Serve H, Horst HA, Schnittger S, Aul C, Schultheis B, Erben P, Schneider S, Müller-Tidow C, Wörmann B, Berdel WE, Sauerland C, Heinecke A, Hehlmann R, Hofmann WK, Hiddemann W, Büchner T; German Acute Myeloid Leukemia Cooperative Group (AMLCG).

Ann Hematol. 2013 Jan;92(1):41-52. doi: 10.1007/s00277-012-1597-9. Epub 2012 Oct 23.

23.

Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes.

Germing U, Strupp C, Giagounidis A, Haas R, Gattermann N, Starke C, Aul C.

Leuk Res. 2012 Jun;36(6):727-34. doi: 10.1016/j.leukres.2012.02.014. Epub 2012 Mar 13.

PMID:
22421409
24.

New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.

Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D.

J Clin Oncol. 2012 Mar 10;30(8):820-9. doi: 10.1200/JCO.2011.35.6394. Epub 2012 Feb 13.

25.

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study.

Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P, Kelaidi C, Pfeilstöcker M, Nösslinger T, Sekeres M, Maciejewski J, Haase D, Schanz J, Seymour J, Kenealy M, Weide R, Lübbert M, Platzbecker U, Valent P, Götze K, Stauder R, Blum S, Kreuzer KA, Schlenk R, Ganser A, Hofmann WK, Aul C, Krieger O, Kündgen A, Haas R, Hasford J, Giagounidis A.

Leukemia. 2012 Jun;26(6):1286-92. doi: 10.1038/leu.2011.391. Epub 2012 Jan 13.

PMID:
22289990
26.

A patient with Fechtner syndrome successfully treated with romiplostim.

Gröpper S, Althaus K, Najm J, Haase S, Aul C, Greinacher A, Giagounidis A.

Thromb Haemost. 2012 Mar;107(3):590-1. doi: 10.1160/TH11-07-0474. Epub 2012 Jan 25. No abstract available.

PMID:
22273764
27.

Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide.

Giagounidis AA, Kulasekararaj A, Germing U, Radkowski R, Haase S, Petersen P, Göhring G, Büsche G, Aul C, Mufti GJ, Platzbecker U.

Leukemia. 2012 Apr;26(4):855-8. doi: 10.1038/leu.2011.268. Epub 2011 Sep 30. No abstract available.

PMID:
21960245
28.

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, Te Boekhorst P, Sanz G, Del Cañizo C, Guerci-Bresler A, Nilsson L, Platzbecker U, Lübbert M, Quesnel B, Cazzola M, Ganser A, Bowen D, Schlegelberger B, Aul C, Knight R, Francis J, Fu T, Hellström-Lindberg E; MDS-004 Lenalidomide del5q Study Group.

Blood. 2011 Oct 6;118(14):3765-76. doi: 10.1182/blood-2011-01-330126. Epub 2011 Jul 13.

29.

Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry.

Neukirchen J, Schoonen WM, Strupp C, Gattermann N, Aul C, Haas R, Germing U.

Leuk Res. 2011 Dec;35(12):1591-6. doi: 10.1016/j.leukres.2011.06.001. Epub 2011 Jun 25.

PMID:
21708407
30.

Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.

Schanz J, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Tuechler H, Valent P, Hildebrandt B, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Kantarjian H, Germing U, Haase D, Estey E.

J Clin Oncol. 2011 May 20;29(15):1963-70. doi: 10.1200/JCO.2010.28.3978. Epub 2011 Apr 25.

31.

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.

Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW.

J Clin Oncol. 2011 May 20;29(15):1987-96. doi: 10.1200/JCO.2010.30.9245. Epub 2011 Apr 11.

PMID:
21483003
32.

Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99.

Passweg JR, Giagounidis AA, Simcock M, Aul C, Dobbelstein C, Stadler M, Ossenkoppele G, Hofmann WK, Schilling K, Tichelli A, Ganser A.

J Clin Oncol. 2011 Jan 20;29(3):303-9. doi: 10.1200/JCO.2010.31.2686. Epub 2010 Dec 13.

PMID:
21149672
33.

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy.

Russwurm G, Heinsch M, Radkowski R, Erlemann R, Aul C, Haase S, Giagounidis A.

Blood. 2010 Oct 7;116(14):2617-8. doi: 10.1182/blood-2010-04-279786. No abstract available.

34.

Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q.

Mallo M, Cervera J, Schanz J, Such E, García-Manero G, Luño E, Steidl C, Espinet B, Vallespí T, Germing U, Blum S, Ohyashiki K, Grau J, Pfeilstöcker M, Hernández JM, Noesslinger T, Giagounidis A, Aul C, Calasanz MJ, Martín ML, Valent P, Collado R, Haferlach C, Fonatsch C, Lübbert M, Stauder R, Hildebrandt B, Krieger O, Pedro C, Arenillas L, Sanz MÁ, Valencia A, Florensa L, Sanz GF, Haase D, Solé F.

Leukemia. 2011 Jan;25(1):110-20. doi: 10.1038/leu.2010.231. Epub 2010 Sep 30.

PMID:
20882045
35.

Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.

Götze K, Platzbecker U, Giagounidis A, Haase D, Lübbert M, Aul C, Ganser A, Germing U, Hofmann WK.

Ann Hematol. 2010 Sep;89(9):841-50. doi: 10.1007/s00277-010-1015-0. Epub 2010 Jun 22. Review.

PMID:
20567826
36.

Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients.

Schroeder T, Ruf L, Bernhardt A, Hildebrandt B, Aivado M, Aul C, Gattermann N, Haas R, Germing U.

Ann Oncol. 2010 Nov;21(11):2267-71. doi: 10.1093/annonc/mdq233. Epub 2010 May 3.

PMID:
20439346
37.

[Myelodysplastic syndromes].

Aul C, Giagounidis A, Germing U.

Internist (Berl). 2010 Feb;51(2):169-82; quiz 183-4. doi: 10.1007/s00108-009-2552-2. German.

PMID:
20082063
38.

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.

Göhring G, Giagounidis A, Büsche G, Kreipe HH, Zimmermann M, Hellström-Lindberg E, Aul C, Schlegelberger B.

Ann Hematol. 2010 Apr;89(4):365-74. doi: 10.1007/s00277-009-0846-z. Epub 2009 Oct 24.

PMID:
19855965
39.

High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG.

Lengfelder E, Haferlach C, Saussele S, Haferlach T, Schultheis B, Schnittger S, Ludwig WD, Staib P, Aul C, Grüneisen A, Kern W, Reichle A, Serve H, Berdel WE, Braess J, Spiekermann K, Wörmann B, Sauerland MC, Heinecke A, Hiddemann W, Hehlmann R, Büchner T; German AML Cooperative Group.

Leukemia. 2009 Dec;23(12):2248-58. doi: 10.1038/leu.2009.183. Epub 2009 Sep 10.

PMID:
19741727
40.

Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil.

Platzbecker U, Aul C, Ehninger G, Giagounidis A.

Ann Hematol. 2010 Apr;89(4):427-8. doi: 10.1007/s00277-009-0824-5. Epub 2009 Aug 28. No abstract available.

PMID:
19714330
41.

Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes.

Neukirchen J, Blum S, Kuendgen A, Strupp C, Aivado M, Haas R, Aul C, Gattermann N, Germing U.

Eur J Haematol. 2009 Nov;83(5):477-82. doi: 10.1111/j.1600-0609.2009.01299.x. Epub 2009 Jun 22.

PMID:
19548919
42.

Meeting report: Vienna 2008 Workshop of the German-Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes.

Valent P, Hofmann WK, Büsche G, Sotlar K, Horny HP, Haase D, Haferlach T, Kern W, Bettelheim P, Baumgartner C, Sperr WR, Nösslinger T, Wimazal F, Giagounidis AA, Lübbert M, Krieger O, Kolb HJ, Stauder R, Pfeilstöcker M, Gattermann N, Fonatsch C, Aul C, Germing U.

Ann Hematol. 2009 Jul;88(7):607-11. doi: 10.1007/s00277-008-0673-7. Epub 2009 Jan 16.

PMID:
19148644
43.

Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.

Büchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Kienast J, Staib P, Grüneisen A, Kern W, Reichle A, Maschmeyer G, Aul C, Lengfelder E, Sauerland MC, Heinecke A, Wörmann B, Hiddemann W.

J Clin Oncol. 2009 Jan 1;27(1):61-9. doi: 10.1200/JCO.2007.15.4245. Epub 2008 Dec 1.

PMID:
19047294
44.

Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes.

Germing U, Aul C, Niemeyer CM, Haas R, Bennett JM.

Ann Hematol. 2008 Sep;87(9):691-9. doi: 10.1007/s00277-008-0499-3. Epub 2008 Jun 25.

PMID:
18575866
45.

Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays.

Wang L, Fidler C, Nadig N, Giagounidis A, Della Porta MG, Malcovati L, Killick S, Gattermann N, Aul C, Boultwood J, Wainscoat JS.

Haematologica. 2008 Jul;93(7):994-1000. doi: 10.3324/haematol.12603. Epub 2008 May 27.

46.

Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes.

Giagounidis AA, Germing U, Haase S, Aul C.

Ther Clin Risk Manag. 2007 Aug;3(4):553-62.

47.

The 5q- syndrome.

Giagounidis AA, Aul C.

Cancer Treat Res. 2008;142:133-48. Review. No abstract available.

PMID:
18283785
48.

New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.

Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Kundgen A, Lübbert M, Kunzmann R, Giagounidis AA, Aul C, Trümper L, Krieger O, Stauder R, Müller TH, Wimazal F, Valent P, Fonatsch C, Steidl C.

Blood. 2007 Dec 15;110(13):4385-95. Epub 2007 Aug 28.

49.

Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.

Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M.

J Clin Oncol. 2007 Aug 10;25(23):3503-10.

PMID:
17687155
50.

Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes.

Mohamedali A, Gäken J, Twine NA, Ingram W, Westwood N, Lea NC, Hayden J, Donaldson N, Aul C, Gattermann N, Giagounidis A, Germing U, List AF, Mufti GJ.

Blood. 2007 Nov 1;110(9):3365-73. Epub 2007 Jul 18.

Supplemental Content

Support Center